Sorafenib Tosylate 99% White Powder CAS 475207-59-1

Sorafenib tosylate 99% white Powder, molecular formula: C28H24ClF3N4O6S, molecular weight: 637.03. It was first developed by Bayer Pharmaceutical Company of Germany. It is a multi-kinase inhibitor and can be used to treat diseases such as cancer. In December 2005, it was approved by FDA as the first-line drug for the treatment of advanced renal cancer, and it was officially listed in China in August 2009 with the approval of the State Food and Drug Administration.

What is Sorafenib tosylate?

Sorafenib tosylate 99% white Powder can simultaneously inhibit a variety of kinases existing in cells and on the cell surface, including RAF kinase, vascular endothelial growth factor receptor -2(VEGFR-2), vascular endothelial growth factor receptor -3(VEGFR-3), platelet-derived growth factor receptor -β(PDGFR-β), KIT and FLT-3. Therefore, it has dual anti-tumor effects. On the one hand, it can directly inhibit tumor growth by inhibiting RAF/MEK/ERK signaling pathway; On the other hand, it can block the formation of tumor neovascularization by inhibiting VEGFR and PDGFR, and indirectly inhibit the growth of tumor cells. Sorafenib tosylate is by far the most effective drug for the treatment of advanced liver cancer by systemic administration, and will probably become a new standard drug for the treatment of this disease.

What are the effects of sorafenib tosylate?

Sorafenib tosylate 99% white Powder was first discovered in biochemical analysis of the structure-activity evaluation of the inhibitor precursor of the c-RAF kinase. Sorafenib tosylate has a strong inhibitory effect on c-RAF, wild type, and mutant b-RAF, and can inhibit serine/threonine kinase activity of c-RAF and b-RAF. Its dual anti-tumor effect is achieved by inhibiting the activity of the above kinases. For RENCA mouse renal cell carcinoma transplantation model, its dosage is 7.5 ~ 90 mg/(kgd), which shows strong anti-tumor activity, and the tumor growth inhibition rate is 30% ~ 80%. During the multi-course administration of the DLD-1 colon cancer transplantation model, the tumor resumed to grow after stopping the treatment, but the tumor growth could still be inhibited after continued administration. In preclinical animal tests, its anti-tumor effect is obviously enhanced when it is combined with chemotherapy drugs such as paclitaxel, irinotecan, gemcitabine, and cisplatin, but the side effects are not increased. When combined with doxorubicin, the dosage of doxorubicin and doxorubicin should be reduced due to the increase in blood exposure concentration.

What are the side effects of using Sorafenib tosylate?

Key safety data of clinical studies in Europe and America supporting the marketing of this product:

1286 patients (mainly white, including a few African-Americans, Asians, Hispanics, and others) were treated with sorafenib tosylate as a single drug. The most common drug-related adverse events are diarrhea, rash, alopecia, and hand-foot syndrome.

Abnormal laboratory examination

After taking sorafenib tosylate, lipase and amylase usually increase.

Asian security data results:

Trial 11515 is a non-randomized, non-controlled, phase II clinical study of sorafenib tosylate in the treatment of advanced renal cancer in Japan. Compared with the key clinical studies in Europe and America, the drug-related adverse events reported in the trial are similar, and the most common ones have increased lipase, hand-foot syndrome, alopecia, increased amylase, rash/desquamation, and diarrhea.

Trial 11559 is a multi-center, non-randomized phase III clinical study of sorafenib tosylate in the treatment of advanced renal cancer in Asia, including the Chinese mainland and Taiwan Province, which is in progress. At present, among all the 29 patients who have been treated with sorafenib tosylate at least once, 21 patients (72.4%) have drug-related adverse events, and the common ones are hand-foot syndrome (27.6%), skin rash (20.7%), hypertension (6.9%), diarrhea (6.9%) and fatigue (6.9%). Sorafenib mesylate showed good safety in the test, and most of the adverse events that occurred were mild and tolerable.

How to choose more products

Send your Inquiry for more details, Click email：allen@faithfulbio.com Now.

You can also contact me via WhatsApp：+86 13137770562

A variety of shipping methods for you to choose

Disclaimer: The articles published on this site are mainly used to promote academic exchanges and learning, and do not mean that this site agrees with its views or confirms the authenticity of its contents. Please filter carefully. If you believe this article is infringing, please contact the administrator. We are not responsible for the consequences of using the information and services on this website.

Note: This compound should be used for research purposes only. These claims have not been evaluated by the Food and Drug Administration. Please consult your doctor and learn about available studies before using them. This product is not intended to diagnose, treat, cure or prevent any disease.

Hot Tags: sorafenib tosylate 99% white powder cas 475207-59-1, China, suppliers, manufacturers, factory, customized, wholesale, buy, price, bulk, pure, producer, discount, for sale, in stock, free sample, raw powder, raw material, made in China